{"id":4152,"date":"2022-06-14T03:38:43","date_gmt":"2022-06-14T03:38:43","guid":{"rendered":"https:\/\/aceoncology.org\/?p=4152"},"modified":"2022-06-14T07:29:23","modified_gmt":"2022-06-14T07:29:23","slug":"fda-new-cancer-indications-approvals-april-may-2022","status":"publish","type":"post","link":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/","title":{"rendered":"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5"},"content":{"rendered":"\n<p>2022\u5e744\u67081\u65e5\u81f35\u670831\u65e5\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Trastuzumab Deruxtecan\u6cbb\u7597\u665a\u671fHER2\u9633\u6027\u4e73\u817a\u764c\u83b7\u5f97\u5e38\u89c4\u5ba1\u6279\u3002<\/strong>HER2\u6297\u4f53-\u836f\u7269\u5076\u8054\u7269fam-trastuzumab deruxtecan-nxki\uff08Enhertu\u00ae\uff0c\u7b2c\u4e00\u4e09\u5171\u516c\u53f8\uff09\u7684\u52a0\u901f\u5ba1\u6279\u5347\u7ea7\u4e3a<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-fam-trastuzumab-deruxtecan-nxki-breast-cancer\">\u5e38\u89c4\u5ba1\u6279<\/a>\uff0c\u88ab\u6279\u51c6\u7528\u4e8e\u65e2\u5f80\u63a5\u53d7\u8fc7\u57fa\u4e8e\u6297HER2\u65b9\u6848\u6cbb\u7597\u7684\u8f6c\u79fb\u6027\u75be\u75c5\u6216\u5728\u5b8c\u6210\u65b0\u8f85\u52a9\/\u8f85\u52a9\u6cbb\u7597\u671f\u95f4\u6216\u6cbb\u7597\u540e6\u4e2a\u6708\u5185\u53d1\u751f\u75be\u75c5\u590d\u53d1\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027HER2\u9633\u6027\u4e73\u817a\u764c\u60a3\u8005\u3002\u8be5\u6279\u51c6\u57fa\u4e8e\u968f\u673a\u3001\u5168\u7403\u3001III\u671f<a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2115022\">DESTINY-Breast03\u8bd5\u9a8c<\/a>\uff08N = 524\uff09\u7684\u7ed3\u679c\uff0c\u8be5\u8bd5\u9a8c\u5728\u63a5\u53d7\u66f2\u59a5\u73e0\u5355\u6297\u548c\u7d2b\u6749\u70f7\u521d\u59cb\u6cbb\u7597\u540e\u7684HER2\u9633\u6027\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u4e2d\u6bd4\u8f83\u4e86trastuzumab deruxtecan\u4e0etrastuzumab emtansine\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002Trastuzumab deruxtecan\u6cbb\u7597\u4ea7\u751f\u4e86\u9ad8\u5ea6\u663e\u8457\u4e14\u5177\u6709\u4e34\u5e8a\u610f\u4e49\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\uff1atrastuzumab deruxtecan\u7ec4\u672a\u8fbe\u5230\u4e2d\u4f4dPFS\uff0c\u800ctrastuzumab emtansine\u7ec4\u4e3a6.8\u4e2a\u6708\uff08\u98ce\u9669\u6bd4[HR]\uff0c0.28\uff1bP &lt; 0.0001\uff09\uff0c\u603b\u751f\u5b58\u671f\uff08OS\uff09\u6570\u636e\u5c1a\u4e0d\u6210\u719f\u3002\u5176\u4e2d\uff0ctrastuzumab deruxtecan\u7ec4\u548ctrastuzumab emtansine\u7ec4\u7684\u603b\u7f13\u89e3\u7387\uff08ORR\uff09\u5206\u522b\u4e3a82.7%\u548c36.1%\u3002\u5904\u65b9\u4fe1\u606f\u5305\u542b\u95f4\u8d28\u6027\u80ba\u75c5\u548c\u80da\u80ce-\u80ce\u513f\u6bd2\u6027\u7684\u9ed1\u6846\u8b66\u544a\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u65b9\u6848\u6cbb\u7597\u98df\u7ba1\u9cde\u72b6\u7ec6\u80de\u764c\u3002<\/strong>\u7eb3\u6b66\u5229\u5c24\u5355\u6297\uff08\u6b27\u72c4\u6c83\u00ae\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff09\u4ee5\u4e24\u79cd\u8054\u5408\u65b9\u6848\u4f5c\u4e3a\u665a\u671f\u6216\u8f6c\u79fb\u6027\u98df\u7ba1\u9cde\u72b6\u7ec6\u80de\u764c\uff08ESCC\uff09\u60a3\u8005\u7684\u4e00\u7ebf\u6cbb\u7597\u83b7\u6279\uff1a\u8054\u5408\u6c1f\u5c3f\u5627\u5576\u548c\u94c2\u7c7b\u4e3a\u57fa\u7840\u7684\u5316\u7597\uff0c\u4ee5\u53ca\u8054\u5408\u4f0a\u5339\u6728\u5355\u6297\uff08\u9038\u6c83\u00ae\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\uff09\u3002<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-opdivo-combination-chemotherapy-and-opdivo-combination-yervoy-first-line-esophageal\">\u8be5\u6279\u51c6<\/a>\u662f\u57fa\u4e8e\u5f00\u653e\u6807\u7b7e\u3001\u968f\u673a\u3001III\u671f<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2111380\">CHECKMATE-648<\/a>\u8bd5\u9a8c\u7684\u7ed3\u679c\uff0c\u8be5\u8bd5\u9a8c\u7eb3\u5165\u4e86970\u4f8b\u65e2\u5f80\u672a\u7ecf\u6cbb\u7597\u7684\u4e0d\u53ef\u5207\u9664\u3001\u665a\u671f\u3001\u590d\u53d1\u6027\u6216\u8f6c\u79fb\u6027ESCC\u60a3\u8005\u3002\u60a3\u8005\u63a5\u53d7\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u6c1f\u5c3f\u5627\u5576\u8054\u5408\u987a\u94c2\uff0c\u6216\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u4f0a\u5339\u6728\u5355\u6297\uff0c\u6216\u6c1f\u5c3f\u5627\u5576\u8054\u5408\u987a\u94c2\u6cbb\u7597\u3002\u672c\u7814\u7a76\u8868\u660e\uff0c\u5728\u603b\u4f53\u4eba\u7fa4\u548c\u80bf\u7624\u7ec6\u80dePD-L1\u8868\u8fbe\u22651%\u7684\u60a3\u8005\u4e2d\uff0c\u4e0e\u5316\u7597\u76f8\u6bd4\uff0c\u4e24\u79cd\u542b\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u7684\u65b9\u6848\u5355\u72ec\u6cbb\u7597\u7684OS\u5747\u6709\u7edf\u8ba1\u5b66\u663e\u8457\u6539\u5584\u3002\u603b\u4f53\u4eba\u7fa4\u4e2d\uff0c\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u6c1f\u5c3f\u5627\u5576\u548c\u987a\u94c2\u7ec4\u7684\u4e2d\u4f4dOS\u4e3a13.2\u4e2a\u6708\uff0c\u5316\u7597\u7ec4\u4e3a10.7\u4e2a\u6708\uff08HR\uff0c0.74\uff1bP = 0.002\uff09\uff0c\u7eb3\u6b66\u5229\u5c24\u5355\u6297\u8054\u5408\u4f0a\u5339\u6728\u5355\u6297\u7ec4\u4e3a12.7\u4e2a\u6708\uff08HR\uff0c0.78\uff1bP = 0.01\uff09\u3002\u5bf9\u4e8ePD-L1\u22651%\u4e9a\u7ec4\uff0cHR\u5206\u522b\u4e3a0.54\uff08P &lt; 0.001\uff09\u548c0.64\uff08P = 0.001\uff09\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u827e\u4f0f\u5c3c\u5e03 + \u963f\u624e\u80de\u82f7\u7528\u4e8e\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u7684\u4e00\u7ebf\u6cbb\u7597\u3002<\/strong>\u827e\u4f0f\u5c3c\u5e03\uff08Tibsovo\u00ae\uff0c\u65bd\u7ef4\u96c5\u516c\u53f8\uff09\u8054\u5408\u963f\u624e\u80de\u82f7<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-combination-azacitidine-newly-diagnosed-acute-myeloid-leukemia\">\u83b7\u6279<\/a>\u7528\u4e8e75\u5c81\u53ca\u4ee5\u4e0a\u6216\u60a3\u6709\u59a8\u788d\u4f7f\u7528\u5f3a\u5316\u8bf1\u5bfc\u5316\u7597\u5408\u5e76\u75c7\u7684\u60a3\u8005\uff0c\u6cbb\u7597\u65b0\u8bca\u65ad\u7684\u643a\u5e26\u6613\u611fIDH1\u7a81\u53d8\u7684\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u3002\u968f\u673a\u3001\u591a\u4e2d\u5fc3\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001III\u671f<a href=\"https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2117344\">AGILE\u7814\u7a76<\/a>\u7684\u7ed3\u679c\u652f\u6301\u8be5\u6279\u51c6\uff0c\u8be5\u7814\u7a76\u4e2d146\u4f8b\u60a3\u8005\u63a5\u53d7\u53e3\u670d\u827e\u4f0f\u5c3c\u5e03\u6216\u5339\u914d\u7684\u5b89\u6170\u5242\u548c\u963f\u624e\u80de\u82f7\uff0c\u76f4\u81f3\u75be\u75c5\u8fdb\u5c55\u3001\u51fa\u73b0\u4e0d\u53ef\u63a5\u53d7\u7684\u6bd2\u6027\u6216\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u3002\u6839\u636e\u5df2\u53d1\u8868\u7684\u6570\u636e\uff0c\u5728\u4e2d\u4f4d\u968f\u8bbf12.4\u4e2a\u6708\u65f6\uff0c\u827e\u4f0f\u5c3c\u5e03\u8054\u5408\u963f\u624e\u80de\u82f7\u7ec4\u7684\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u663e\u8457\u957f\u4e8e\u5b89\u6170\u5242\u8054\u5408\u963f\u624e\u80de\u82f7\u7ec4\uff08HR\uff0c0.33\uff1bP = 0.002\uff09\u3002\u827e\u4f0f\u5c3c\u5e03\u8054\u5408\u963f\u624e\u80de\u82f7\u7ec4\u7684\u4e2d\u4f4dOS\u4e3a24.0\u4e2a\u6708\uff0c\u5b89\u6170\u5242\u8054\u5408\u963f\u624e\u80de\u82f7\u7ec4\u4e3a7.9\u4e2a\u6708\uff08HR\uff0c0.44\uff1bP = 0.001\uff09\u3002\u827e\u4f0f\u5c3c\u5e03\u8054\u5408\u963f\u624e\u80de\u82f7\u7ec4\u8fd1\u4e00\u534a\u7684\u60a3\u8005\uff0847%\uff09\u83b7\u5f97\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\uff0c\u800c\u5b89\u6170\u5242\u8054\u5408\u963f\u624e\u80de\u82f7\u7ec4\u4e3a15%\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u963f\u624e\u80de\u82f7\u7528\u4e8e\u65b0\u8bca\u65ad\u7684\u5e7c\u5e74\u7c92\u5355\u6838\u7ec6\u80de\u767d\u8840\u75c5\u3002<\/strong>\u963f\u624e\u80de\u82f7\u5355\u836f\u6cbb\u7597\uff08Vidaza\u00ae\uff0c\u65b0\u57fa\u516c\u53f8\uff09<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-azacitidine-newly-diagnosed-juvenile-myelomonocytic-leukemia\">\u83b7\u6279<\/a>\u7528\u4e8e\u65b0\u8bca\u65ad\u7684\u5e7c\u5e74\u578b\u7c92\u5355\u6838\u7ec6\u80de\u767d\u8840\u75c5\uff08JMML\uff09\u513f\u7ae5\u60a3\u8005\u3002\u8be5\u6279\u51c6\u662f\u57fa\u4e8e\u4e00\u9879\u56fd\u9645\u3001\u591a\u4e2d\u5fc3\u3001\u5f00\u653e\u6027\u3001II\u671f<a href=\"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/14\/2901\/476417\/\">AZA-JMML-001<\/a>\u8bd5\u9a8c\uff0c\u8be5\u8bd5\u9a8c\u572818\u4f8bJMML\u60a3\u8005\u4e2d\u8bc4\u4f30\u4e86\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\uff08HSCT\uff09\u524d\u963f\u624e\u80de\u82f7\u7684\u836f\u4ee3\u52a8\u529b\u5b66\u3001\u836f\u6548\u5b66\u3001\u5b89\u5168\u6027\u548c\u6d3b\u6027\u3002\u4e3b\u8981\u7597\u6548\u89c2\u5bdf\u6307\u6807\u4e3a\u4e34\u5e8a\u5b8c\u5168\u7f13\u89e3\uff08cCR\uff09\u6216\u4e34\u5e8a\u90e8\u5206\u7f13\u89e3\uff08cPR\uff09\u3002\u534a\u6570\u60a3\u8005\u5df2\u8bc1\u5b9e\u4e34\u5e8a\u7f13\u89e3\uff0c\u5176\u4e2d3\u4f8bcCR\uff0c6\u4f8bcPR\u3002\u63a5\u53d7HSCT\u7684\u60a3\u8005\u6bd4\u4f8b\u4e3a94%\uff0c\u4e2d\u4f4d\u81f3HSCT\u65f6\u95f4\u4e3a4.6\u4e2a\u6708\u3002\u5728\u63a5\u53d7HSCT\u768417\u4f8b\u60a3\u8005\u4e2d\uff0c14\u4f8b\uff0882%\uff09\u5728HSCT\u540e\u4e2d\u4f4d\u968f\u8bbf23.8\u4e2a\u6708\u65f6\u65e0\u767d\u8840\u75c5\u3002<\/li><\/ul>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>\u4e24\u79cd\u6297CD19\u5d4c\u5408\u6297\u539f\u53d7\u4f53\uff08CAR\uff09T\u7ec6\u80de\u7597\u6cd5\u6cbb\u7597\u6dcb\u5df4\u7624\u7684\u65b0\u9002\u5e94\u75c7\uff1a<\/strong><br><br><em>Tisa-Cel\u6cbb\u7597\u590d\u53d1\u6216\u96be\u6cbb\u6027\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\u3002<\/em>Tisagenlecleucel\uff08Tisa-cel\uff0cKymriah\u00ae\uff0c\u8bfa\u534e\u516c\u53f8\uff09\u83b7\u5f97<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-relapsed-or-refractory-follicular-lymphoma\">\u52a0\u901f\u6279\u51c6<\/a>\uff0c\u7528\u4e8e\u4e8c\u7ebf\u6216\u591a\u7ebf\u5168\u8eab\u6cbb\u7597\u540e\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\uff08R\/R FL\uff09\u6210\u4eba\u60a3\u8005\u3002\u8be5\u6279\u51c6\u57fa\u4e8e\u591a\u4e2d\u5fc3\u3001\u5355\u7ec4\u3001II\u671f<a href=\"https:\/\/ash.confex.com\/ash\/2021\/webprogram\/Paper149327.html\">ELARA\u8bd5\u9a8c<\/a>\uff0c\u8be5\u8bd5\u9a8c\u5728\u63a5\u53d7\u8fc7\u81f3\u5c11\u4e24\u7ebf\u5168\u8eab\u6cbb\u7597\uff08\u5305\u62ec\u6297CD20\u6297\u4f53\u548c\u70f7\u5316\u5242\uff09\u6216\u81ea\u4f53HSCT\u540e\u590d\u53d1\u7684R\/R FL\u60a3\u8005\u4e2d\u8bc4\u4ef7\u4e86Tisa-cel\u7684\u7597\u6548\u3002\u5728\u4e3b\u8981\u7597\u6548\u5206\u6790\u768490\u4f8b\u60a3\u8005\u4e2d\uff0cORR\u4e3a86%\uff0c\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u7387\u4e3a68%\u3002\u4e2d\u4f4d\u7f13\u89e3\u6301\u7eed\u65f6\u95f4\u672a\u8fbe\u5230\uff0c75%\u7684\u7f13\u89e3\u8005\u57289\u4e2a\u6708\u65f6\u4ecd\u6709\u7f13\u89e3\u300298\u4f8b\u63a5\u53d7\u767d\u7ec6\u80de\u5206\u79bb\u672f\u7684\u60a3\u8005\u7684ORR\u4e3a86%\uff0cCR\u7387\u4e3a67%\u3002<br><br><em>Axi-Cel\u7528\u4e8e\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\u7684\u4e8c\u7ebf\u6cbb\u7597\u3002<\/em>Axicabtagene ciloleucel\uff08Yescarta\u00ae\uff0cKite Pharma\u516c\u53f8\uff09<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma\">\u83b7\u6279<\/a>\u7528\u4e8e\u4e00\u7ebf\u5316\u5b66\u514d\u75ab\u6cbb\u7597\u96be\u6cbb\u6216\u4e00\u7ebf\u5316\u5b66\u514d\u75ab\u6cbb\u7597\u540e12\u4e2a\u6708\u5185\u590d\u53d1\u7684\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\uff08LBCL\uff09\u60a3\u8005\u3002\u9002\u5e94\u75c7\u4e0d\u5305\u62ec\u539f\u53d1\u6027\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u6dcb\u5df4\u7624\u60a3\u8005\u7684\u6cbb\u7597\u3002\u8be5\u6279\u51c6\u5f97\u5230\u4e86\u968f\u673a\u3001\u5f00\u653e\u6027\u3001\u591a\u4e2d\u5fc3\u3001III\u671f<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2116133\">ZUMA-7<\/a>\u8bd5\u9a8c\u7ed3\u679c\u7684\u652f\u6301\uff0c\u8be5\u8bd5\u9a8c\u7eb3\u5165\u4e86356\u4f8b\u65e9\u671f\u96be\u6cbb\u6027\u75be\u75c5\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u5c1a\u672a\u63a5\u53d7\u590d\u53d1\u6027\u6216\u96be\u6cbb\u6027\u6dcb\u5df4\u7624\u7684\u6cbb\u7597\uff0c\u5e76\u4e14\u662f\u81ea\u4f53HSCT\u7684\u6f5c\u5728\u5019\u9009\u8005\u3002\u60a3\u8005\u5728\u6dcb\u5df4\u7ec6\u80de\u8017\u7aed\u5316\u7597\u540e\u968f\u673a\u63a5\u53d7axi-cel\u6216\u4e8c\u7ebf\u6807\u51c6\u6cbb\u7597\uff0c\u968f\u540e\u5728\u83b7\u5f97\u5b8c\u5168\u7f13\u89e3\u6216\u90e8\u5206\u7f13\u89e3\u7684\u60a3\u8005\u4e2d\u63a5\u53d7\u9ad8\u5242\u91cf\u6cbb\u7597\u548c\u81ea\u4f53HSCT\u3002\u5728\u4e2d\u4f4d\u968f\u8bbf24.9\u4e2a\u6708\u65f6\uff0caxi-cel\u7ec4\u548c\u6807\u51c6\u6cbb\u7597\u7ec4\u7684\u4e2d\u4f4dEFS\u5206\u522b\u4e3a8.3\u4e2a\u6708\u548c2.0\u4e2a\u6708\uff0c24\u4e2a\u6708EFS\u7387\u5206\u522b\u4e3a41%\u548c16%\uff08HR\uff0c0.40\uff1bP &lt; 0.001\uff09\u3002axi-cel\u7ec483%\u7684\u60a3\u8005\u548c\u6807\u51c6\u6cbb\u7597\u7ec450%\u7684\u60a3\u8005\u51fa\u73b0\u7f13\u89e3\uff0cCR\u5206\u522b\u4e3a65%\u548c32%\u3002<br><br>Tisa-Cel\u548cAxi-Cel\u7684\u5904\u65b9\u4fe1\u606f\u5747\u5305\u542b\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u7efc\u5408\u5f81\u548c\u795e\u7ecf\u6bd2\u6027\u7684\u9ed1\u6846\u8b66\u544a\u3002<\/li><\/ul>\n\n\n\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div class=\"wp-block-group\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><\/div><\/div>\n<\/div><\/div>\n\n\n\n<ul class=\"wp-block-list\"><li><strong>Alpelisib\u6cbb\u7597PIK3CA\u76f8\u5173\u8fc7\u5ea6\u751f\u957f\u8c31\u3002<\/strong>alpelisib\uff08Vijoice\u00ae\uff0c\u8bfa\u534e\u5236\u836f\uff09\u83b7\u5f97<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum\">\u52a0\u901f\u6279\u51c6<\/a>\uff0c\u7528\u4e8e\u9700\u8981\u5168\u8eab\u6cbb\u7597\u7684\u6709PIK3CA\u76f8\u5173\u8fc7\u5ea6\u751f\u957f\u8c31\uff08PROS\uff09\u91cd\u5ea6\u8868\u73b0\u7684\u6210\u4eba\u548c\u22652\u5c81\u513f\u7ae5\u60a3\u8005\u3002PROS\u662f\u4e00\u7ec4\u5f02\u8d28\u6027\u7f55\u89c1\u75be\u75c5\uff0c\u7531\u4e8ePIK3CA\u57fa\u56e0\u7a81\u53d8\u5bfc\u81f4\u673a\u4f53\u8fc7\u5ea6\u751f\u957f\u3002\u6279\u51c6\u662f\u57fa\u4e8e<a href=\"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(21)04401-X\/fulltext\">EPIK-P1\u8bd5\u9a8c<\/a>\uff0c\u8fd9\u662f\u4e00\u9879\u56de\u987e\u6027\u3001\u5355\u7ec4\u56fe\u8868\u8bc4\u4ef7\uff0c\u63d0\u4f9b\u4e86\u4f5c\u4e3a\u540c\u60c5\u7528\u836f\u7684\u8bb0\u540d\u4f9b\u836f\u8ba1\u5212\u7684\u4e00\u90e8\u5206\u63a5\u53d7alpelisib\u7684PROS\u60a3\u8005\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u3002\u572837\u4f8b\u5177\u6709\u5371\u53ca\u751f\u547d\u7684PROS\u4e34\u5e8a\u8868\u73b0\u7684PIK3CA\u7a81\u53d8\u60a3\u8005\u4e2d\u8bc4\u4ef7\u4e86<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum\">Alpelisib\u7684\u7597\u6548<\/a>\uff0c\u8fd9\u4e9b\u60a3\u8005\u5728\u63a5\u53d7\u9996\u6b21\u7ed9\u836f\u524d24\u5468\u5185\u8fdb\u884c\u7684CT\u6210\u50cf\u4e2d\u81f3\u5c11\u786e\u5b9a\u4e86\u4e00\u4e2a\u9776\u75c5\u7076\u3002\u4e3b\u8981\u7597\u6548\u7ed3\u5c40\u6307\u6807\u4e3a\u7b2c24\u5468\u65f6\u51fa\u73b0\u653e\u5c04\u5b66\u7f13\u89e3\u7684\u60a3\u8005\u6bd4\u4f8b\uff0c\u5b9a\u4e49\u4e3a\u901a\u8fc7\u81f3\u5c111\u6b21\u540e\u7eed\u5f71\u50cf\u5b66\u8bc4\u4f30\u786e\u8ba4\u7684\u6700\u591a3\u5904\u75c5\u7076\u4e2d\u53ef\u6d4b\u91cf\u9776\u75c5\u7076\u4f53\u79ef\u4e4b\u548c\u8f83\u57fa\u7ebf\u51cf\u5c11\u226520%\u3002\u5728\u7b2c24\u5468\uff0c27%\u7684\u60a3\u8005\u51fa\u73b0\u653e\u5c04\u5b66\u7f13\u89e3\uff0c60%\u7684\u7f13\u89e3\u60a3\u8005\u7f13\u89e3\u6301\u7eed12\u4e2a\u6708\u53ca\u4ee5\u4e0a\u3002<\/li><\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>2022\u5e744\u67081\u65e5\u81f35\u670831\u65e5\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002 Trastuzumab Deruxteca [&hellip;]<\/p>\n","protected":false},"author":691,"featured_media":4067,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42],"tags":[],"class_list":["post-4152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-42"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology<\/title>\n<meta name=\"description\" content=\"2022\u5e744\u6708\u81f35\u6708\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology\" \/>\n<meta property=\"og:description\" content=\"2022\u5e744\u6708\u81f35\u6708\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"ACE Oncology\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-14T03:38:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-14T07:29:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"526\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"j gao\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:site\" content=\"@ace_oncology\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"j gao\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\"},\"author\":{\"name\":\"j gao\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf\"},\"headline\":\"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\",\"datePublished\":\"2022-06-14T03:38:43+00:00\",\"dateModified\":\"2022-06-14T07:29:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\"},\"wordCount\":146,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg\",\"articleSection\":[\"\u65b0\u836f\u83b7\u6279\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\",\"url\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\",\"name\":\"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology\",\"isPartOf\":{\"@id\":\"https:\/\/aceoncology.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg\",\"datePublished\":\"2022-06-14T03:38:43+00:00\",\"dateModified\":\"2022-06-14T07:29:23+00:00\",\"description\":\"2022\u5e744\u6708\u81f35\u6708\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg\",\"width\":1000,\"height\":526},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"ACE Oncology\",\"item\":\"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/aceoncology.org\/#website\",\"url\":\"https:\/\/aceoncology.org\/\",\"name\":\"ACE Oncology\",\"description\":\"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.\",\"publisher\":{\"@id\":\"https:\/\/aceoncology.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/aceoncology.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/aceoncology.org\/#organization\",\"name\":\"ACE Oncology\",\"url\":\"https:\/\/aceoncology.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"contentUrl\":\"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png\",\"width\":156,\"height\":83,\"caption\":\"ACE Oncology\"},\"image\":{\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ace_oncology\",\"https:\/\/www.linkedin.com\/company\/aceoncology\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf\",\"name\":\"j gao\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/aceoncology.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g\",\"caption\":\"j gao\"},\"url\":\"https:\/\/aceoncology.org\/zh-hans\/author\/jgao\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology","description":"2022\u5e744\u6708\u81f35\u6708\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/","og_locale":"zh_CN","og_type":"article","og_title":"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology","og_description":"2022\u5e744\u6708\u81f35\u6708\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002","og_url":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/","og_site_name":"ACE Oncology","article_published_time":"2022-06-14T03:38:43+00:00","article_modified_time":"2022-06-14T07:29:23+00:00","og_image":[{"width":1000,"height":526,"url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg","type":"image\/jpeg"}],"author":"j gao","twitter_card":"summary_large_image","twitter_creator":"@ace_oncology","twitter_site":"@ace_oncology","twitter_misc":{"\u4f5c\u8005":"j gao","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#article","isPartOf":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/"},"author":{"name":"j gao","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf"},"headline":"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5","datePublished":"2022-06-14T03:38:43+00:00","dateModified":"2022-06-14T07:29:23+00:00","mainEntityOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/"},"wordCount":146,"commentCount":0,"publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg","articleSection":["\u65b0\u836f\u83b7\u6279"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/","url":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/","name":"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5 - ACE Oncology","isPartOf":{"@id":"https:\/\/aceoncology.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage"},"image":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg","datePublished":"2022-06-14T03:38:43+00:00","dateModified":"2022-06-14T07:29:23+00:00","description":"2022\u5e744\u6708\u81f35\u6708\uff0c\u7f8e\u56fdFDA\u5171\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5\u3002","breadcrumb":{"@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#primaryimage","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2022\/06\/Picture-Blog-Post-57_Drug-approvals-August_Middle-Size.jpg","width":1000,"height":526},{"@type":"BreadcrumbList","@id":"https:\/\/aceoncology.org\/zh-hans\/fda-new-cancer-indications-approvals-april-may-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"ACE Oncology","item":"https:\/\/aceoncology.org\/zh-hans\/chinese-home\/"},{"@type":"ListItem","position":2,"name":"2022\u5e744\u6708-5\u6708FDA\u6279\u51c67\u9879\u65b0\u7684\u80bf\u7624\u7597\u6cd5"}]},{"@type":"WebSite","@id":"https:\/\/aceoncology.org\/#website","url":"https:\/\/aceoncology.org\/","name":"ACE Oncology","description":"ACE Oncology is a global independent medical education resource that provides evidence-based, high-quality educational solutions for clinicians that treat patients with cancer.","publisher":{"@id":"https:\/\/aceoncology.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/aceoncology.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/aceoncology.org\/#organization","name":"ACE Oncology","url":"https:\/\/aceoncology.org\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/","url":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","contentUrl":"https:\/\/aceoncology.org\/wp-content\/uploads\/2021\/05\/Logo.png","width":156,"height":83,"caption":"ACE Oncology"},"image":{"@id":"https:\/\/aceoncology.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ace_oncology","https:\/\/www.linkedin.com\/company\/aceoncology"]},{"@type":"Person","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/ccad8f084cde5a6cf908e3c506262fdf","name":"j gao","image":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/aceoncology.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afe10fca3d4cc45c0cd0b8bf85070e61056e2c5e5c887f814736bbe9e6243d1e?s=96&d=mm&r=g","caption":"j gao"},"url":"https:\/\/aceoncology.org\/zh-hans\/author\/jgao\/"}]}},"_links":{"self":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/4152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/users\/691"}],"replies":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/comments?post=4152"}],"version-history":[{"count":5,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/4152\/revisions"}],"predecessor-version":[{"id":4159,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/posts\/4152\/revisions\/4159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media\/4067"}],"wp:attachment":[{"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/media?parent=4152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/categories?post=4152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aceoncology.org\/zh-hans\/wp-json\/wp\/v2\/tags?post=4152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}